Schedule

Content should explore the rapid growth of ADC pipelines and the increasing technical complexity of manufacturing these highly potent, targeted therapies. Coverage can focus on payload-linker chemistry, containment strategies for HPAPIs, scalable conjugation processes, and analytical challenges in ensuring stability and efficacy. Editorial can also examine how CDMOs, equipment suppliers, and single-use system providers are enabling safe, flexible ADC production while meeting evolving regulatory expectations. Position sponsors as solution partners supporting the transition from clinical-scale to commercial ADC manufacturing.

This theme should highlight how digital twin modelling, AI-driven analytics, and integrated data platforms are transforming facility design, process optimisation, and lifecycle management. Articles can examine real-world case studies of predictive maintenance, virtual process simulation, and real-time performance monitoring in biologics manufacturing. Focus on how sponsors’ software, sensors, automation platforms, and MES solutions help manufacturers reduce downtime, improve validation efficiency, and support regulatory compliance through data integrity and transparency.

Coverage should explore how robotics and automated systems are reducing human intervention, increasing throughput, and enhancing sterility assurance in pharmaceutical production. Feature insights into robotic aseptic filling, modular continuous manufacturing skids, closed processing systems, and flexible automation designed for small-batch and personalised medicines. Emphasise how sponsors’ technologies enable scalable, repeatable processes while supporting lean manufacturing principles and cost-efficiency in high-growth therapeutic segments.

Content should focus on contamination control strategies, Annex 1 compliance, and next-generation sterile manufacturing technologies. Articles can address isolators, RABS, rapid microbial methods, environmental monitoring systems, and advanced cleanroom design. Highlight how equipment and technology providers are helping manufacturers strengthen sterility assurance levels, manage risk proactively, and adapt facilities to increasingly stringent regulatory expectations. Position sponsors as critical partners in ensuring product safety, patient protection, and operational resilience.

The U.S. pharmaceutical manufacturing landscape is evolving at an unprecedented pace, driven by breakthroughs in AI, next-generation biologics, and rapidly shifting regulatory and market dynamics. For suppliers and service providers, these trends present a prime opportunity to align solutions with the industry’s most pressing needs.

Artificial intelligence and advanced analytics are reshaping drug development, process optimisation, and quality control. From predictive maintenance in manufacturing equipment to AI-driven formulation and supply chain insights, pharma companies are seeking technology partners who can deliver efficiency, compliance, and innovation at scale.

The rise of next-gen biologics - including cell and gene therapies, novel protein therapeutics, and personalised medicines - is creating demand for specialized raw materials, advanced manufacturing platforms, and contract development and manufacturing expertise. Suppliers positioned to provide precision, scalability, and regulatory support will be essential in helping manufacturers bring these therapies to market.

Navigating the global pharma regulatory environment, evolving pricing policies, and market access challenges requires real-time intelligence and agile solutions. Companies providing compliance tools, regulatory consulting, and data-driven insights are increasingly valued as strategic partners, enabling pharma manufacturers to stay ahead of policy changes while maintaining operational excellence.

CPHI 2026 preview - Pharma manufacturers are facing increasing pressure to secure resilient, diversified, and regulatory-compliant API and excipient supply chains amid ongoing geopolitical disruption and capacity constraints. At the same time, rising molecule complexity -particularly in biologics and specialty medicines is reshaping formulation requirements, forcing closer collaboration between developers and ingredient suppliers to ensure scalability, consistency, and speed to market. As APIs become more specialised and globally sourced, manufacturers are focusing on supply security, formulation adaptability, and faster transition from development to scalable production, particularly in high-growth therapeutic areas such as biologics and specialty medicines. We'll explore how ingredient sourcing is shifting from cost optimisation to supply security and formulation partnership models.

CPHI 2026 preview - Pharma manufacturing is moving toward greater digital integration, but adoption remains uneven across global production networks. Manufacturing 5.0 is driving investment in automation, AI-enabled quality control, and real-time data systems, yet manufacturers must balance digital transformation with strict GMP compliance and legacy infrastructure constraints. The key challenge is scaling innovation across multiple sites while maintaining validated, repeatable processes. We'll investigate how Manufacturing 5.0 is delivering real value, and where implementation is still lagging

CPHI 2026 preview - A deep dive into how packaging suppliers are evolving from traditional containment providers into strategic partners in integrated drug delivery. As biologics and self-administered therapies drive demand for more patient-centric treatment models, packaging is playing an increasingly important role in compliance, usability, traceability, and therapeutic performance. Suppliers are investing in pre-filled systems, autoinjectors, connected packaging, and advanced traceability technologies, while also responding to growing regulatory scrutiny and sustainability expectations across materials, design, and lifecycle management.

CPHI Milan 2026 will feature a Sustainability Summit. Sustainability targets are increasingly shaping procurement decisions across pharma supply chains, but implementation is complex in temperature-sensitive logistics. The expansion of biologics and vaccines is placing additional strain on cold chain infrastructure, driving demand for energy-efficient systems, emissions tracking, and supply chain optimisation tools. Companies are now balancing ESG commitments with the need for uninterrupted global distribution of high-value medicines. Content will look at how pharma supply chains are balancing ESG commitments with the operational realities of cold chain expansion.

Global tensions, trade policies, and regulatory divergence are influencing sourcing, manufacturing, and distribution strategies. Suppliers who can provide risk mitigation tools, alternative sourcing solutions, and compliance guidance help pharma companies navigate uncertainty while maintaining operational continuity.

The expansion of cell and gene therapies, immunotherapies, and personalized medicines is redefining manufacturing requirements. There is growing demand for specialized equipment, high-quality raw materials, and flexible manufacturing services - opportunities for suppliers to position themselves as critical partners in bringing next-gen therapies to market.

From IoT-enabled process monitoring to predictive analytics and fully integrated digital ecosystems, smart manufacturing is transforming efficiency, quality, and traceability. Technology providers offering connected solutions, automation platforms, and AI-driven insights are becoming indispensable collaborators in modern pharma production.

Recent disruptions have highlighted the critical importance of resilient, transparent, and agile supply chains. Suppliers who can deliver end-to-end visibility, real-time analytics, and contingency solutions empower manufacturers to manage risk, ensure continuity, and meet growing regulatory expectations.